It is for each Health Board to determine its prescribing policy on medicines, including Riluzole, taking into account the advice provided by their Drug and Therapeutic Committee.In 1996, Riluzole was granted a Marketing Authorisation valid for the European Union on the basis of the dossier submitted to the European Medicines Evaluation Agency (EMEA).